Advertisement






Click here for more guidelines.
CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 1999; 34:1512-1521
© 1999 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Buffon, A.
Right arrow Articles by Maseri, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Buffon, A.
Right arrow Articles by Maseri, A.

CLINICAL STUDIES

Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty

Antonino Buffon, MDa, Giovanna Liuzzo, MDa, Luigi M. Biasucci, MD, FACCa, Patrizio Pasqualetti, PhD*, Vito Ramazzotti, MDa, Antonio G. Rebuzzi, MDa, Filippo Crea, MD, FACCa and Attilio Maseri, MD, FACCa

a Istituto di Cardiologia, Università Cattolica del Sacro Cuore, Rome, Italy
* A.Fa.R., Ospedale Fetebenefratelli-Isola Tiberina, Rome, Italy

Manuscript received October 1, 1998; revised manuscript received March 25, 1999, accepted June 28, 1999.

Reprint requests and correspondence: Dr. Antonino Buffon, Istituto di Cardiologia, Università Cattolica del Sacro Cuore, Largo Gemelli, 8 - 00168 Rome, Italy.
abuffon{at}mail.OMNITEL.IT

OBJECTIVES

We sought to investigate whether early and late outcome after percutaneous transluminal coronary angioplasty (PTCA) could be predicted by baseline levels of acute-phase reactants.

BACKGROUND

Although some risk factors for acute complications and restenosis have been identified, an accurate preprocedural risk stratification of patients undergoing PTCA is still lacking.

METHODS

Levels of C-reactive protein (CRP), serum amyloid A protein (SAA) and fibrinogen were measured in 52 stable angina and 69 unstable angina patients undergoing single vessel PTCA.

RESULTS

Tertiles of CRP levels (relative risk [RR] = 12.2, p < 0.001), systemic hypertension (RR = 4.3, p = 0.046) and female gender (RR = 4.1, p = 0.033) were the only independent predictors of early adverse events. Intraprocedural and in-hospital complications were observed in 22% of 69 patients with high serum levels (>0.3 mg/dl) of CRP and in none of 52 patients with normal CRP levels (p < 0.001). Tertiles of CRP levels (RR = 6.2, p = 0.001), SAA levels (RR = 6.0, p = 0.011), residual stenosis (RR = 3.2, p = 0.007) and acute gain (RR = 0.3, p = 0.01) were the only independent predictors of clinical restenosis. At one-year follow-up, clinical restenosis developed in 63% of patients with high CRP levels and in 27% of those with normal CRP levels (p < 0.001).

CONCLUSIONS

Preprocedural CRP level, an easily measurable marker of acute phase response, is a powerful predictor of both early and late outcome in patients undergoing single vessel PTCA, suggesting that early complications and clinical restenosis are markedly influenced by the preprocedural degree of inflammatory cell activation.

Abbreviations and Acronyms
  CABG = coronary bypass graft surgery
  CI = confidence interval
  CRP = C-reactive protein
  ECG = electrocardiogram
  MI = myocardial infarction
  PTCA = percutaneous transluminal coronary angioplasty
  RR = relative risk
  SAA = serum amyloid A protein
  TIMI = Thrombolysis in Myocardial Infarction




This article has been cited by other articles:


Home page
HeartHome page
D. Tousoulis, N. Papageorgiou, and C. Stefanadis
Is C-reactive protein a prognostic marker after angioplasty?
Heart, June 15, 2009; 95(12): 957 - 959.
[Full Text] [PDF]


Home page
HeartHome page
W C Kang, T H Ahn, C I Moon, S H Han, E K Shin, J-S Kim, Y-G Ko, D Choi, Y Jang, B-K Kim, et al.
Comparison of inflammatory markers and angiographic outcomes after implantation of sirolimus and paclitaxel-eluting stents
Heart, June 15, 2009; 95(12): 970 - 975.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
R Iijima, R A Byrne, G Ndrepepa, S Braun, J Mehilli, P B Berger, A Schomig, and A Kastrati
Pre-procedural C-reactive protein levels and clinical outcomes after percutaneous coronary interventions with and without abciximab: pooled analysis of four ISAR trials
Heart, January 15, 2009; 95(2): 107 - 112.
[Abstract] [Full Text] [PDF]


Home page
Ther Adv Cardiovasc DisHome page
S. Jimenez-Valero, R. Moreno, A. Sanchez-Recalde, G. Galeote, L. Calvo, A. Viana, E. Lopez de Sa, and J. Lopez-Sendon
Review: Avoiding restenosis: is there a role for glucocorticoids in the drug-eluting stent era?
Therapeutic Advances in Cardiovascular Disease, June 1, 2008; 2(3): 137 - 146.
[Abstract] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
S. Kinlay, G. G. Schwartz, A. G. Olsson, N. Rifai, M. Szarek, D. D. Waters, P. Libby, P. Ganz, and for the Myocardial Ischemia Reduction with Aggress
Inflammation, Statin Therapy, and Risk of Stroke After an Acute Coronary Syndrome in the MIRACL Study
Arterioscler Thromb Vasc Biol, January 1, 2008; 28(1): 142 - 147.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Neuroradiol.Home page
K. Groschel, U. Ernemann, J. Larsen, M. Knauth, F. Schmidt, J. Artschwager, and A. Kastrup
Preprocedural C-Reactive Protein Levels Predict Stroke and Death in Patients Undergoing Carotid Stenting
AJNR Am. J. Neuroradiol., October 1, 2007; 28(9): 1743 - 1746.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
F. G. Hage and A. J. Szalai
C-Reactive Protein Gene Polymorphisms, C-Reactive Protein Blood Levels, and Cardiovascular Disease Risk
J. Am. Coll. Cardiol., September 18, 2007; 50(12): 1115 - 1122.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
D.-W. Park, C. W. Lee, S.-C. Yun, Y.-H. Kim, M.-K. Hong, J.-J. Kim, S.-W. Park, and S.-J. Park
Prognostic impact of preprocedural C reactive protein levels on 6-month angiographic and 1-year clinical outcomes after drug-eluting stent implantation
Heart, September 1, 2007; 93(9): 1087 - 1092.
[Abstract] [Full Text] [PDF]


Home page
Vasc MedHome page
S. R. Steinhubl, J. J. Badimon, D. L. Bhatt, J.-M. Herbert, and T. F. Luscher
Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease
Vascular Medicine, May 1, 2007; 12(2): 113 - 122.
[Abstract] [PDF]


Home page
Eur. J. Cardiothorac. Surg.Home page
T. Palmerini, A. Marzocchi, C. Marrozzini, L. B. Reggiani, C. Savini, G. Marinelli, R. Di Bartolomeo, and A. Branzi
Preoperative C-reactive protein levels predict 9-month mortality after coronary artery bypass grafting surgery for the treatment of left main coronary artery stenosis
Eur. J. Cardiothorac. Surg., April 1, 2007; 31(4): 685 - 690.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
B. Assmus, D. H. Walter, R. Lehmann, J. Honold, H. Martin, S. Dimmeler, A. M. Zeiher, and V. Schachinger
Intracoronary infusion of progenitor cells is not associated with aggravated restenosis development or atherosclerotic disease progression in patients with acute myocardial infarction
Eur. Heart J., December 2, 2006; 27(24): 2989 - 2995.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
D. J. Angiolillo, A. Fernandez-Ortiz, E. Bernardo, C. Ramirez, M. Sabate, P. Jimenez-Quevedo, R. Hernandez, R. Moreno, J. Escaned, F. Alfonso, et al.
Clopidogrel Withdrawal Is Associated With Proinflammatory and Prothrombotic Effects in Patients With Diabetes and Coronary Artery Disease
Diabetes, March 1, 2006; 55(3): 780 - 784.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
D. A. Pascual, J. M. Arribas, P. L. Tornel, F. Marin, C. Oliver, M. Ahumada, J. Gomez-Plana, P. Martinez, R. Arcas, and M. Valdes
Preoperative Statin Therapy and Troponin T Predict Early Complications of Coronary Artery Surgery
Ann. Thorac. Surg., January 1, 2006; 81(1): 78 - 83.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
J. Herrmann
Peri-procedural myocardial injury: 2005 update
Eur. Heart J., December 1, 2005; 26(23): 2493 - 2519.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
N. Saleh, B. Svane, L.-O. Hansson, J. Jensen, T. Nilsson, O. Danielsson, and P. Tornvall
Response of Serum C-Reactive Protein to Percutaneous Coronary Intervention Has Prognostic Value
Clin. Chem., November 1, 2005; 51(11): 2124 - 2130.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
S.-J. Park
Inflammatory Biomarkers for Prediction of Outcomes After Unprotected Left Main Coronary Intervention
Circulation, October 11, 2005; 112(15): 2226 - 2227.
[Full Text] [PDF]


Home page
CirculationHome page
T. Palmerini, A. Marzocchi, C. Marrozzini, P. Ortolani, F. Saia, L. Bacchi-Reggiani, S. Virzi, S. Gianstefani, and A. Branzi
Preprocedural Levels of C-Reactive Protein and Leukocyte Counts Predict 9-Month Mortality After Coronary Angioplasty for the Treatment of Unprotected Left Main Coronary Artery Stenosis
Circulation, October 11, 2005; 112(15): 2332 - 2338.
[Abstract] [Full Text] [PDF]


Home page
LupusHome page
L M Biasucci, G Giubilato, F Graziani, and M Piro
CRP is or is not a reliable marker of ischaemic heart disease?
Lupus, September 1, 2005; 14(9): 752 - 755.
[Abstract] [PDF]


Home page
CirculationHome page
L. M. Biasucci
CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: Clinical Use of Inflammatory Markers in Patients With Cardiovascular Diseases: A Background Paper
Circulation, December 21, 2004; 110(25): e560 - e567.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
K. Toutouzas, A. Colombo, and C. Stefanadis
Inflammation and restenosis after percutaneous coronary interventions
Eur. Heart J., October 1, 2004; 25(19): 1679 - 1687.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
D. A. Morrow
Preprocedural C-Reactive Protein for Risk Prediction Before Percutaneous Coronary Intervention (PCI): A US Perspective
Clin. Chem., September 1, 2004; 50(9): 1489 - 1491.
[Full Text] [PDF]


Home page
Clin. Chem.Home page
L. M. Biasucci and G. G.L. Biondi-Zoccai
Preprocedural C-Reactive Protein for Risk Prediction Before Percutaneous Coronary Intervention (PCI): A European Perspective
Clin. Chem., September 1, 2004; 50(9): 1492 - 1494.
[Full Text] [PDF]


Home page
Clin. Chem.Home page
S. Z.H. Rittersma, R. J. de Winter, K. T. Koch, C. E. Schotborgh, M. Bax, G. S. Heyde, J. P. van Straalen, K. J. Mulder, J. G.P. Tijssen, G. T. Sanders, et al.
Preprocedural C-Reactive Protein Is Not Associated with Angiographic Restenosis or Target Lesion Revascularization after Coronary Artery Stent Placement
Clin. Chem., September 1, 2004; 50(9): 1589 - 1596.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
F. Blaschke, D. Bruemmer, F. Yin, Y. Takata, W. Wang, M. C. Fishbein, T. Okura, J. Higaki, K. Graf, E. Fleck, et al.
C-Reactive Protein Induces Apoptosis in Human Coronary Vascular Smooth Muscle Cells
Circulation, August 3, 2004; 110(5): 579 - 587.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
A. Segev, S. Kassam, C. E Buller, H. K Lau, J. D Sparkes, P. W Connelly, P. H Seidelin, M. K Natarajan, E. A Cohen, and B. H Strauss
Pre-procedural plasma levels of C-reactive protein and interleukin-6 do not predict late coronary angiographic restenosis after elective stenting
Eur. Heart J., June 2, 2004; 25(12): 1029 - 1035.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
M N Zairis, J A Ambrose, A G Lyras, M A Thoma, P K Psarogianni, P G Psaltiras, A D Kardoulas, G P Bibis, E G Pissimissis, P C Batika, et al.
C Reactive protein, moderate alcohol consumption, and long term prognosis after successful coronary stenting: four year results from the GENERATION study
Heart, April 1, 2004; 90(4): 419 - 424.
[Abstract] [Full Text] [PDF]


Home page
The Annals of PharmacotherapyHome page
J. M Backes, P. A Howard, and P. M Moriarty
Role of C-Reactive Protein in Cardiovascular Disease
Ann. Pharmacother., January 1, 2004; 38(1): 110 - 118.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
H. D. Danenberg, G. Golomb, A. Groothuis, J. Gao, H. Epstein, R. V. Swaminathan, P. Seifert, and E. R. Edelman
Liposomal Alendronate Inhibits Systemic Innate Immunity and Reduces In-Stent Neointimal Hyperplasia in Rabbits
Circulation, December 2, 2003; 108(22): 2798 - 2804.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
F. Cipollone, C. Ferri, G. Desideri, L. Paloscia, G. Materazzo, M. Mascellanti, M. Fazia, A. Iezzi, C. Cuccurullo, B. Pini, et al.
Preprocedural Level of Soluble CD40L Is Predictive of Enhanced Inflammatory Response and Restenosis After Coronary Angioplasty
Circulation, December 2, 2003; 108(22): 2776 - 2782.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
F. Biancari, J. Lahtinen, S. Lepojarvi, P. Rainio, E. Salmela, R. Pokela, M. Lepojarvi, J. Satta, and T. S. Juvonen
Preoperative C-reactive protein and outcome after coronary artery bypass surgery
Ann. Thorac. Surg., December 1, 2003; 76(6): 2007 - 2012.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
S. Verma, M. V. Badiwala, R. D. Weisel, S.-H. Li, C.-H. Wang, P. W. M. Fedak, R.-K. Li, and D. A. G. Mickle
C-reactive protein activates the nuclear factor-{kappa}B signal transduction pathway in saphenous vein endothelial cells: implications for atherosclerosis and restenosis
J. Thorac. Cardiovasc. Surg., December 1, 2003; 126(6): 1886 - 1891.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
P. M Ridker and on behalf of the JUPITER Study Group
Rosuvastatin in the Primary Prevention of Cardiovascular Disease Among Patients With Low Levels of Low-Density Lipoprotein Cholesterol and Elevated High-Sensitivity C-Reactive Protein: Rationale and Design of the JUPITER Trial*
Circulation, November 11, 2003; 108(19): 2292 - 2297.
[Full Text] [PDF]


Home page
Eur Heart JHome page
T.-M. Lu, Y.-A. Ding, S.-J. Lin, W.-S. Lee, and H.-C. Tai
Plasma levels of asymmetrical dimethylarginine and adverse cardiovascular events after percutaneous coronary intervention
Eur. Heart J., November 1, 2003; 24(21): 1912 - 1919.
[Abstract] [Full Text] [PDF]


Home page
QJMHome page
G.M. Hirschfield and M.B. Pepys
C-reactive protein and cardiovascular disease: new insights from an old molecule
QJM, November 1, 2003; 96(11): 793 - 807.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
B. M. Rahel, F. L.J. Visseren, M.-J. Suttorp, T. H.W. Plokker, J. C. Kelder, B. M. de Jongh, K.P. Bouter, and R. J.A. Diepersloot
Preprocedural serum levels of acute-phase reactants and prognosis after percutaneous coronary intervention
Cardiovasc Res, October 15, 2003; 60(1): 136 - 140.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
H S Gurm, D L Bhatt, A M Lincoff, J E Tcheng, D J Kereiakes, N S Kleiman, G Jia, and E J Topol
Impact of preprocedural white blood cell count on long term mortality after percutaneous coronary intervention: insights from the EPIC, EPILOG, and EPISTENT trials
Heart, October 1, 2003; 89(10): 1200 - 1204.
[Abstract] [Full Text] [PDF]


Home page
SEMIN CARDIOTHORAC VASC ANESTHHome page
S. V. Dee and H. Samady
Evolving Strategies for the Prevention and Treatment of Coronary Restenosis
Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 2003; 7(3): 281 - 293.
[Abstract] [PDF]


Home page
HeartHome page
F Cipollone, M Fazia, A Iezzi, B Pini, F Costantini, D De Cesare, L Paloscia, G Materazzo, E D'Annunzio, T Bucciarelli, et al.
High preprocedural non-HDL cholesterol is associated with enhanced oxidative stress and monocyte activation after coronary angioplasty: possible implications in restenosis
Heart, July 1, 2003; 89(7): 773 - 779.
[Abstract] [Full Text] [PDF]


Home page
RadiologyHome page
M. Schillinger, M. Exner, W. Mlekusch, M. Haumer, H. Rumpold, R. Ahmadi, S. Sabeti, O. Wagner, and E. Minar
Endovascular Revascularization Below the Knee: 6-month Results and Predictive Value of C-reactive Protein Level
Radiology, May 1, 2003; 227(2): 419 - 425.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
A. W. Chan, D. L. Bhatt, D. P. Chew, J. Reginelli, J. P. Schneider, E. J. Topol, and S. G. Ellis
Relation of Inflammation and Benefit of Statins After Percutaneous Coronary Interventions
Circulation, April 8, 2003; 107(13): 1750 - 1756.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
G. G. L. Biondi-Zoccai, A. Abbate, G. Liuzzo, and L. M. Biasucci
Atherothrombosis, inflammation, and diabetes
J. Am. Coll. Cardiol., April 2, 2003; 41(7): 1071 - 1077.
[Abstract] [Full Text] [PDF]


Home page
Arch SurgHome page
M. A. Zimmerman, C. H. Selzman, C. Cothren, A. C. Sorensen, C. D. Raeburn, and A. H. Harken
Diagnostic Implications of C-Reactive Protein
Arch Surg, February 1, 2003; 138(2): 220 - 224.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
T Lenderink, E Boersma, C Heeschen, A Vahanian, M.-J de Boer, V Umans, M.J.B.M van den Brand, C.W Hamm, M.L Simoons, and for the CAPTURE investigators
Elevated troponin T and C-reactive protein predict impaired outcome for 4 years in patients with refractory unstable angina, and troponin T predicts benefit of treatment with abciximab in combination with PTCA
Eur. Heart J., January 1, 2003; 24(1): 77 - 85.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
F. Versaci, A. Gaspardone, F. Tomai, F. Ribichini, P. Russo, I. Proietti, A. S. Ghini, V. Ferrero, L. Chiariello, P. Agostino Gioffre, et al.
Immunosuppressive therapy for the prevention of restenosis after coronary artery stent implantation (IMPRESS study)
J. Am. Coll. Cardiol., December 4, 2002; 40(11): 1935 - 1942.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
J. Herrmann, A. Lerman, D. Baumgart, L. Volbracht, R. Schulz, C. von Birgelen, M. Haude, G. Heusch, and R. Erbel
Preprocedural Statin Medication Reduces the Extent of Periprocedural Non-Q-Wave Myocardial Infarction
Circulation, October 22, 2002; 106(17): 2180 - 2183.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
M. N. Zairis, J. A. Ambrose, S. J. Manousakis, A. S. Stefanidis, O. A. Papadaki, H. I. Bilianou, M. C. DeVoe, C. N. Fakiolas, E. G. Pissimissis, C. D. Olympios, et al.
The impact of plasma levels of C-reactive protein, lipoprotein (a) and homocysteine on the long-term prognosis after successful coronary stenting: The global evaluation of new events and restenosis after stent implantation study
J. Am. Coll. Cardiol., October 16, 2002; 40(8): 1375 - 1382.
[Abstract] [Full Text] [PDF]


Home page
RadiologyHome page
M. Schillinger, M. Exner, W. Mlekusch, H. Rumpold, R. Ahmadi, S. Sabeti, M. Haumer, O. Wagner, and E. Minar
Vascular Inflammation and Percutaneous Transluminal Angioplasty of the Femoropopliteal Artery: Association with Restenosis
Radiology, October 1, 2002; 225(1): 21 - 26.
[Abstract] [Full Text] [PDF]


Home page
RadiologyHome page
M. Schillinger, M. Exner, W. Mlekusch, M. Haumer, R. Ahmadi, H. Rumpold, O. Wagner, and E. Minar
Inflammatory Response to Stent Implantation: Differences in Femoropopliteal, Iliac, and Carotid Arteries
Radiology, August 1, 2002; 224(2): 529 - 535.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
D. L. Bhatt and E. J. Topol
Need to Test the Arterial Inflammation Hypothesis
Circulation, July 2, 2002; 106(1): 136 - 140.
[Full Text] [PDF]


Home page
CirculationHome page
H. D. Danenberg, F. G. P. Welt, M. Walker III, P. Seifert, G. S. Toegel, and E. R. Edelman
Systemic Inflammation Induced by Lipopolysaccharide Increases Neointimal Formation After Balloon and Stent Injury in Rabbits
Circulation, June 18, 2002; 105(24): 2917 - 2922.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
R.J. de Winter, G.S. Heyde, K.T. Koch, J. Fischer, J.P. van Straalen, M. Bax, C.E. Schotborgh, K.J. Mulder, G.T. Sanders, J.J. Piek, et al.
The prognostic value of pre-procedural plasma C-reactive protein in patients undergoing elective coronary angioplasty
Eur. Heart J., June 2, 2002; 23(12): 960 - 966.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
D. H. Walter, S. Fichtlscherer, M. B. Britten, P. Rosin, W. Auch-Schwelk, V. Schachinger, and A. M. Zeiher
Statin therapy, inflammation and recurrent coronary events in patients following coronary stent implantation
J. Am. Coll. Cardiol., December 1, 2001; 38(7): 2006 - 2012.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
W. R. P. Agema, J. W. Jukema, S. N. Pimstone, and J. J. P. Kastelein
Genetic aspects of restenosis after percutaneous coronary interventions;towards more tailored therapy
Eur. Heart J., November 2, 2001; 22(22): 2058 - 2074.
[PDF]


Home page
Circ. Res.Home page
G. J. Blake and P. M. Ridker
Novel Clinical Markers of Vascular Wall Inflammation
Circ. Res., October 26, 2001; 89(9): 763 - 771.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
P. A. Gum, M. Thamilarasan, J. Watanabe, E. H. Blackstone, and M. S. Lauer
Aspirin Use and All-Cause Mortality Among Patients Being Evaluated for Known or Suspected Coronary Artery Disease: A Propensity Analysis
JAMA, September 12, 2001; 286(10): 1187 - 1194.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
D. P. Chew, D. L. Bhatt, M. A. Robbins, M. S. Penn, J. P. Schneider, M. S. Lauer, E. J. Topol, and S. G. Ellis
Incremental Prognostic Value of Elevated Baseline C-Reactive Protein Among Established Markers of Risk in Percutaneous Coronary Intervention
Circulation, August 28, 2001; 104(9): 992 - 997.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
A. M. Lincoff, D. J. Kereiakes, M. A. Mascelli, L. I. Deckelbaum, E. S. Barnathan, K. K. Patel, B. Frederick, M. T. Nakada, and E. J. Topol
Abciximab Suppresses the Rise in Levels of Circulating Inflammatory Markers After Percutaneous Coronary Revascularization
Circulation, July 10, 2001; 104(2): 163 - 167.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
D. H. Walter, S. Fichtlscherer, M. Sellwig, W. Auch-Schwelk, V. Schachinger, and A. M. Zeiher
Preprocedural C-reactive protein levels and cardiovascular events after coronary stent implantation
J. Am. Coll. Cardiol., March 1, 2001; 37(3): 839 - 846.
[Abstract] [Full Text] [PDF]


Home page
BMJHome page
M. B Pepys and A. Berger
The renaissance of C reactive protein
BMJ, January 6, 2001; 322(7277): 4 - 5.
[Full Text] [PDF]


Home page
Eur Heart JHome page
W. Wijns and F. Ribichini
CRP: does it stand for C oronary R estenosis P rediction?
Eur. Heart J., July 2, 2000; 21(14): 1121 - 1123.
[PDF]


Home page
CirculationHome page
E. Rossi, L. M. Biasucci, F. Citterio, S. Pelliccioni, C. Monaco, F. Ginnetti, D. J. Angiolillo, G. Grieco, G. Liuzzo, and A. Maseri
Risk of Myocardial Infarction and Angina in Patients With Severe Peripheral Vascular Disease: Predictive Role of C-Reactive Protein
Circulation, February 19, 2002; 105(7): 800 - 803.
[Abstract] [Full Text] [PDF]



 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement